GoldenTree backs Alvotech with $100m financing to accelerate pipeline execution
Alvotech secures $100M loan to fund 2026 biosimilar launches and R&D. Find out how this financing reshapes its global strategy.
How XORTX is linking gout to genetics and reshaping the future of precision uric acid therapies
XORTX is using new genetic research to strengthen its case for oxypurinol in gout and kidney disease. Find out how this could shape the future of precision nephrology.
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia’s biosimilar adoption. Find out what this means.
Why Kashiv BioSciences’ Gujarat plant expansion could redefine biomanufacturing in India
Kashiv BioSciences raises INR 648 crore to expand its Gujarat biologics facility. Find out what this means for India’s role in global drug manufacturing.
NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
How Agenus is taking aim at cold tumors with Fc-enhanced anti-CTLA-4 therapy
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.
Can Vyriad’s VV169 redefine CAR T therapy with single-dose in vivo delivery?
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.